Susan Murphy

Q: What Schools Are Affiliated With Susan Murphy

Susan Murphy is affiliated with the following schools: Stanford University, Johns Hopkins University, University of Bern, University of North Carolina at Chapel Hill, University of Oulu, University of Texas Southwestern Medical Center, Harvard University, University of Vermont, University of California, Berkeley, University of Michigan, Louisiana State University, Icahn School of Medicine at Mount Sinai, United States Military Academy, Massachusetts General Hospital, New York University, Kyoto University

Susan Murphy's AcademicInfluence.com Rankings

Susan Murphy

Mathematics

#2557

World Rank

#3922

Historical Rank

#1004

USA Rank

Statistics

#101

World Rank

#133

Historical Rank

#47

USA Rank

mathematics Degrees

Download Badge

Mathematics

Susan Murphy's Degrees

PhD Statistics Stanford University

Why Is Susan Murphy Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Susan Allbritton Murphy is an American statistician, known for her work applying statistical methods to clinical trials of treatments for chronic and relapsing medical conditions. She is a professor at Harvard University, a MacArthur Fellow, and a member of the National Academy of Sciences.

(See a Problem?)

Susan Murphy's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Prasugrel versus clopidogrel in patients with acute coronary syndromes. (2007) (6103)
MONOGRAPHS ON STATISTICS AND APPLIED PROBABILITY (2007) (4759)
Edoxaban versus warfarin in patients with atrial fibrillation. (2013) (3988)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) (3562)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes (2019) (2285)
Rivaroxaban in patients with a recent acute coronary syndrome. (2012) (1745)
The prevention and treatment of missing data in clinical trials. (2012) (1495)
TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation: An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy (2000) (1462)
Long-term use of ticagrelor in patients with prior myocardial infarction. (2015) (1399)
Clopidogrel with or without omeprazole in coronary artery disease. (2010) (1106)
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial (2009) (1082)
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. (2011) (1065)
Just-in-Time Adaptive Interventions (JITAIs) in Mobile Health: Key Components and Design Principles for Ongoing Health Behavior Support (2017) (1000)
Prasugrel Compared With High Loading– and Maintenance–Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 Trial (2007) (905)
Myocardial infarction accelerates atherosclerosis (2012) (880)
Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. (2000) (868)
Vorapaxar in the secondary prevention of atherothrombotic events. (2012) (839)
The multiphase optimization strategy (MOST) and the sequential multiple assignment randomized trial (SMART): new methods for more potent eHealth interventions. (2007) (829)
Mobile health technology evaluation: the mHealth evidence workshop. (2013) (800)
Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide (2002) (756)
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 (2008) (744)
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials (2009) (741)
Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. (2006) (739)
Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. (2005) (735)
Diabetes and mortality following acute coronary syndromes. (2007) (670)
Hospital Delays in Reperfusion for ST-Elevation Myocardial Infarction: Implications When Selecting a Reperfusion Strategy (2006) (574)
A Conceptual Framework for Adaptive Preventive Interventions (2004) (565)
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. (2008) (562)
Race and gender differences in C-reactive protein levels. (2005) (556)
Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary Syndromes (2005) (530)
Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. (2007) (507)
PERFORMANCE GUARANTEES FOR INDIVIDUALIZED TREATMENT RULES. (2011) (478)
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial (2008) (467)
Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. (2008) (465)
Combination Therapy With Abciximab Reduces Angiographically Evident Thrombus in Acute Myocardial Infarction: A TIMI 14 Substudy (2001) (465)
Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes (2003) (460)
Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. (2003) (454)
Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. (2006) (452)
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) (2017) (447)
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. (2019) (424)
Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. (1999) (424)
A "SMART" design for building individualized treatment sequences. (2012) (419)
Challenges in Evaluating Psychosocial Interventions for Autistic Spectrum Disorders (2005) (414)
Microrandomized trials: An experimental design for developing just-in-time adaptive interventions. (2015) (413)
Soluble CD40L: Risk Prediction After Acute Coronary Syndromes (2003) (409)
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. (2017) (403)
Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction (2004) (398)
Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y12 Antagonist, With Clopidogrel in Percutaneous Coronary Intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)–TIMI 26 Trial (2005) (398)
A strategy for optimizing and evaluating behavioral interventions (2005) (396)
Association Between White Blood Cell Count, Epicardial Blood Flow, Myocardial Perfusion, and Clinical Outcomes in the Setting of Acute Myocardial Infarction: A Thrombolysis In Myocardial Infarction 10 Substudy (2000) (393)
Relationship of the TIMI Myocardial Perfusion Grades, Flow Grades, Frame Count, and Percutaneous Coronary Intervention to Long-Term Outcomes After Thrombolytic Administration in Acute Myocardial Infarction (2002) (389)
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. (2019) (386)
On Profile Likelihood (2000) (382)
Marginal Mean Models for Dynamic Regimes (2001) (380)
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials (2019) (377)
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial (2015) (345)
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. (2008) (327)
Communication interventions for minimally verbal children with autism: a sequential multiple assignment randomized trial. (2014) (306)
Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. (2003) (297)
Asymptotic Theory for the Frailty Model (1995) (295)
Benefit of an early invasive management strategy in women with acute coronary syndromes. (2002) (291)
A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy (2001) (291)
Introduction to SMART designs for the development of adaptive interventions: with application to weight loss research (2014) (289)
Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. (2000) (289)
Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. (2014) (288)
Maximum Likelihood Estimation in the Proportional Odds Model (1997) (287)
Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. (2004) (281)
Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes (2002) (268)
Lipoprotein-Associated Phospholipase A2 and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction) Trial (2006) (256)
Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT (2015) (253)
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. (2009) (252)
Consistency in a Proportional Hazards Model Incorporating a Random Effect (1994) (247)
Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. (2005) (229)
Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial (2015) (225)
ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators. (2000) (225)
What Is the Optimal Blood Pressure in Patients After Acute Coronary Syndromes?: Relationship of Blood Pressure and Cardiovascular Events in the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction (PROVE IT-TIMI) 22 Trial (2010) (223)
The Effect of Routine, Early Invasive Management on Outcome for Elderly Patients with NonST-Segment Elevation Acute Coronary Syndromes (2004) (222)
B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. (2004) (222)
Vorapaxar in Patients With Peripheral Artery Disease: Results From TRA2°P-TIMI 50 (2013) (219)
Experimental design and primary data analysis methods for comparing adaptive interventions. (2012) (216)
From hype to reality: data science enabling personalized medicine (2018) (203)
Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial (2016) (202)
Differential Expression of Cardiac Biomarkers by Gender in Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction: A TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy–Thrombolysis In Myocardial Infarction 18) Substudy (2004) (200)
Developing adaptive treatment strategies in substance abuse research. (2007) (199)
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. (2019) (192)
Prognostic Utility of Heart-Type Fatty Acid Binding Protein in Patients With Acute Coronary Syndromes (2006) (190)
Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (2009) (190)
A Generalization Error for Q-Learning (2005) (187)
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. (2008) (187)
Treatment Sequencing for Childhood ADHD: A Multiple-Randomization Study of Adaptive Medication and Behavioral Interventions (2016) (186)
Relationship Between C-Reactive Protein and Subclinical Atherosclerosis: The Dallas Heart Study (2005) (183)
Clinical Benefit of Statin Pretreatment in Patients Undergoing Percutaneous Coronary Intervention: A Collaborative Patient-Level Meta-Analysis of 13 Randomized Studies (2011) (181)
Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. (2016) (181)
Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. (2002) (177)
Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). (2007) (177)
Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. (2003) (176)
Informing sequential clinical decision-making through reinforcement learning: an empirical study (2010) (175)
Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. (2009) (174)
Designing a pilot sequential multiple assignment randomized trial for developing an adaptive treatment strategy (2012) (173)
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. (2016) (173)
Early glycoprotein IIb–IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis (2008) (172)
Inflammatory and Cholesterol Risk in the FOURIER Trial (2018) (172)
TIMI Myocardial Perfusion Grade and ST Segment Resolution: Association With Infarct Size as Assessed by Single Photon Emission Computed Tomography Imaging (2002) (172)
U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. (2005) (171)
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER (2018) (171)
Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. (2007) (170)
Time-dependent coefficients in a Cox-type regression model (1991) (169)
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial (2015) (154)
Inference for non-regular parameters in optimal dynamic treatment regimes (2010) (153)
Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. The TIMI Study Group. Thrombolysis in myocardial infarction. (1999) (151)
Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. (2017) (151)
Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) (149)
Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes ☆: A TACTICS-TIMI 18 substudy (2003) (148)
Evaluation of the Glycometabolic Effects of Ranolazine in Patients With and Without Diabetes Mellitus in the MERLIN-TIMI 36 Randomized Controlled Trial (2009) (148)
Q-learning: a data analysis method for constructing adaptive interventions. (2012) (147)
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial (2008) (146)
Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. (2004) (145)
Dynamic treatment regimes: technical challenges and applications. (2014) (144)
6. Discrete-Time Multilevel Hazard Analysis (2000) (141)
The Theil-Sen Estimator with Doubly Censored Data and Applications to Astronomy (1995) (139)
Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: a TACTICS-TIMI-18 substudy. (2005) (139)
From Ads to Interventions: Contextual Bandits in Mobile Health (2017) (138)
Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. (2012) (137)
Elevations in Troponin T and I Are Associated With Abnormal Tissue Level Perfusion: A TACTICS-TIMI 18 Substudy (2002) (137)
Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I. (2010) (136)
Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). (2002) (136)
Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction. (2004) (129)
Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis. (2016) (128)
Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. (2005) (127)
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus (2020) (127)
Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction (2016) (126)
Efficacy of Contextually Tailored Suggestions for Physical Activity: A Micro-randomized Optimization Trial of HeartSteps. (2018) (125)
Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. (2012) (125)
Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol: A Prespecified Analysis of the IMPROVE-IT Trial (2017) (124)
Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis (2018) (124)
A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. (2006) (123)
Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. (2006) (120)
Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48) (2017) (116)
Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. (2007) (115)
Association of Cystatin C With Left Ventricular Structure and Function: The Dallas Heart Study (2009) (114)
Association of peripheral neutrophilia with adverse angiographic outcomes in ST-elevation myocardial infarction. (2004) (113)
Just-in-Time Adaptive Interventions (JITAIs): An Organizing Framework for Ongoing Health Behavior Support (2014) (111)
ACC/AHA/ESC/WHF Universal Definition of Myocardial Infarction Classification System and the Risk of Cardiovascular Death: Observations from the TRITON-TIMI 38 Trial (2011) (110)
Methodological Challenges in Constructing Effective Treatment Sequences for Chronic Psychiatric Disorders (2007) (110)
A Tale of Two Trials: A Comparison of the Post–Acute Coronary Syndrome Lipid-Lowering Trials A to Z and PROVE IT–TIMI 22 (2006) (110)
Multimarker Risk Stratification in Patients With Acute Myocardial Infarction (2016) (109)
Detection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: observations from the PROTECT-TIMI 30 Trial. (2009) (109)
Dynamic Treatment Regimes. (2014) (108)
Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25. (2007) (107)
Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. (2006) (106)
Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. (2002) (105)
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis (2009) (105)
To Prompt or Not to Prompt? A Microrandomized Trial of Time-Varying Push Notifications to Increase Proximal Engagement With a Mobile Health App (2018) (105)
The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. (2007) (100)
Associations Between Soluble CD40 Ligand, Atherosclerosis Risk Factors, and Subclinical Atherosclerosis: Results from the Dallas Heart Study (2005) (100)
Assessing Time-Varying Causal Effect Moderation in Mobile Health (2016) (100)
Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. (2006) (99)
Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study. (2009) (99)
Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial (2016) (95)
Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51). (2013) (95)
Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. (2011) (94)
Evidence-based practice for rehabilitation professionals: concepts and controversies. (2012) (94)
An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. (2012) (93)
Linear fitted-Q iteration with multiple reward functions (2013) (91)
Developing multicomponent interventions using fractional factorial designs (2009) (91)
Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. (2021) (90)
Customizing treatment to the patient: adaptive treatment strategies. (2007) (88)
Association of platelet counts on presentation and clinical outcomes in ST-elevation myocardial infarction (from the TIMI Trials). (2006) (88)
Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF‐TIMI 48 Trial (2018) (87)
Efficacy and Safety of Vorapaxar in Patients With Prior Ischemic Stroke (2013) (87)
Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial (2018) (87)
Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) (2017) (87)
Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36). (2014) (87)
Sample size calculations for micro‐randomized trials in mHealth (2015) (86)
Left Ventricular Hypertrophy, Subclinical Atherosclerosis, and Inflammation (2007) (86)
Protocol: Adaptive Implementation of Effective Programs Trial (ADEPT): cluster randomized SMART trial comparing a standard versus enhanced implementation strategy to improve outcomes of a mood disorders program (2014) (86)
Semiparametric likelihood ratio inference (1997) (84)
Association of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study). (2008) (83)
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). (2007) (82)
Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. (2015) (82)
Validation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry. (2002) (81)
Investigation of 2 Types of Self-administered Acupressure for Persistent Cancer-Related Fatigue in Breast Cancer Survivors: A Randomized Clinical Trial. (2016) (80)
Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. (2007) (80)
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. (2019) (80)
Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy. (2002) (79)
Evaluation of the association of proximal coronary culprit artery lesion location with clinical outcomes in acute myocardial infarction. (2003) (79)
Efficient Reinforcement Learning with Multiple Reward Functions for Randomized Controlled Trial Analysis (2010) (79)
Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) (2016) (78)
Variable Selection for Qualitative Interactions. (2011) (78)
Determinants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial Infarction. (1999) (76)
Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF‐TIMI 48 (2014) (75)
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial (2017) (74)
Angiographic and Clinical Outcomes in Patients Receiving Low-Molecular-Weight Heparin Versus Unfractionated Heparin in ST-Elevation Myocardial Infarction Treated With Fibrinolytics in the CLARITY-TIMI 28 Trial (2005) (74)
Relationship between fall-related efficacy and activity engagement in community-dwelling older adults: a meta-analytic review. (2012) (73)
Plasma Osteoprotegerin Levels in the General Population: Relation to Indices of Left Ventricular Structure and Function (2007) (73)
Batch mode reinforcement learning based on the synthesis of artificial trajectories (2013) (72)
Observed information in semi-parametric models (1999) (72)
Angiographic perfusion score: an angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction. (2004) (71)
Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. (2016) (71)
Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States (2015) (71)
Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. (2017) (70)
Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. (2011) (69)
The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. (2006) (69)
The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. (2016) (68)
Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry. (2003) (67)
Adaptive Confidence Intervals for the Test Error in Classification (2011) (67)
Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. (2008) (67)
Clinical Features and Outcomes of Women With Unstable Ischemic Heart Disease: Observations From Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST-Elevation Acute Coronary Syndromes–Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) (2010) (66)
Likelihood Ratio-Based Confidence Intervals in Survival Analysis (1995) (66)
Structural Nested Mean Models for Assessing Time‐Varying Effect Moderation (2010) (66)
Independent associations between metabolic syndrome, diabetes mellitus and atherosclerosis: observations from the Dallas Heart Study (2008) (66)
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis (2020) (65)
Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction (2015) (65)
Benefit of Intensive Statin Therapy in Women: Results From PROVE IT-TIMI 22 (2011) (65)
Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study. (2008) (65)
Central obesity and cardiovascular outcomes in patients with acute coronary syndrome: observations from the MERLIN-TIMI 36 trial (2011) (64)
Comparison of a phased experimental approach and a single randomized clinical trial for developing multicomponent behavioral interventions (2009) (63)
The Smoker's Paradox: Insights from the Angiographic Substudies of the TIMI Trials (2002) (63)
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study (2019) (62)
A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of th (2009) (62)
Personalized HeartSteps: A Reinforcement Learning Algorithm for Optimizing Physical Activity (2019) (62)
Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes. (2012) (61)
The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies. (2002) (61)
Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). (2001) (61)
Center of Excellence for Mobile Sensor Data-to-Knowledge (MD2K) (2015) (59)
Facilitating evidence-based practice: process, strategies, and resources. (2010) (58)
Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes. (2003) (57)
Dynamic TIMI Risk Score for STEMI (2013) (57)
Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy. (2005) (56)
Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction. (2004) (56)
Screening experiments and the use of fractional factorial designs in behavioral intervention research. (2008) (56)
B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. (2010) (56)
Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes. (2002) (56)
Constructing evidence-based treatment strategies using methods from computer science. (2007) (55)
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial. (2019) (55)
Decreased substance use in chronically psychotic patients treated with clozapine. (1994) (55)
Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. (2016) (55)
Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy. (2008) (55)
Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial. (2005) (54)
Distance from the Coronary Ostium to the Culprit Lesion in Acute ST-Elevation Myocardial Infarction and its Implications Regarding the Potential Prevention of Proximal Plaque Rupture (2003) (54)
A-Learning for approximate planning (2004) (54)
Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. (2004) (53)
Efficacy and safety of multivessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes. (2002) (53)
Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. (2018) (53)
Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial. (2006) (53)
Influence of Race on Death and Ischemic Complications in Patients With Non–ST-Elevation Acute Coronary Syndromes Despite Modern, Protocol-Guided Treatment (2005) (52)
Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin: Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (2014) (52)
4. Adjusting for Time-Varying Confounding in Survival Analysis (2004) (52)
Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy. (2001) (51)
Intervention fidelity: a necessary aspect of intervention effectiveness studies. (2012) (51)
Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. (2001) (51)
Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial. (2014) (50)
A risk score to estimate the likelihood of coronary artery bypass surgery during the index hospitalization among patients with unstable angina and non-ST-segment elevation myocardial infarction. (2004) (50)
Association Between Platelet Receptor Occupancy After Eptifibatide (Integrilin) Therapy and Patency, Myocardial Perfusion, and ST-Segment Resolution Among Patients With ST-Segment–Elevation Myocardial Infarction: An INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) Substudy (2004) (50)
Inference for Batched Bandits (2020) (50)
A Pilot SMART for Developing an Adaptive Treatment Strategy for Adolescent Depression (2016) (50)
Testing for a Time Dependent Coefficient in Cox's Regression Model (1993) (50)
Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†. (2015) (49)
An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. (2020) (49)
An Actor-Critic Contextual Bandit Algorithm for Personalized Mobile Health Interventions (2017) (48)
Serum Levels of the Interleukin-1 Receptor Family Member ST 2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction (2004) (48)
Organization and staffing practices in US cardiac intensive care units: a survey on behalf of the American Heart Association Writing Group on the Evolution of Critical Care Cardiology (2013) (48)
Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. (2015) (47)
Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. (2017) (47)
Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In (2014) (47)
Randomised trials for the Fitbit generation (2015) (46)
Initial clinical experience with distal protection using the FilterWire in patients undergoing coronary artery and saphenous vein graft percutaneous intervention (2002) (46)
Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy. (2002) (45)
Comparison of B-type natriuretic peptide levels in patients with heart failure with versus without mitral regurgitation. (2004) (45)
Myonecrosis following stent placement: association between impaired TIMI myocardial perfusion grade and MRI visualization of microinfarction. (2002) (45)
High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis. (2008) (44)
Adaptive Treatment Strategies: an Emerging Approach for Improving Treatment Effectiveness (2003) (43)
Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) (2017) (43)
Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results. The TIMI Study Group. (1999) (43)
Occupational therapy in fall prevention: current evidence and future directions. (2012) (43)
The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12 Inhibitor in Patients After Percutaneous Coronary Intervention (2020) (43)
Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial. (2010) (42)
BATCH POLICY LEARNING IN AVERAGE REWARD MARKOV DECISION PROCESSES. (2020) (42)
Micro-Randomized Trials : An Experimental Design for Developing Just-inTime Adaptive Interventions (2015) (42)
Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis (2021) (42)
Cost-Effectiveness of Coronary Stenting and Abciximab for Patients With Acute Myocardial Infarction: Results From the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial (2003) (41)
Screening Experiments for Developing Dynamic Treatment Regimes (2009) (40)
Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). (2013) (40)
Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial. (2001) (40)
Off-Policy Estimation of Long-Term Average Outcomes With Applications to Mobile Health (2019) (40)
Observed Information in Semiparametric Models (39)
Activity pacing in daily life: A within-day analysis (2014) (39)
Knowledge and production of English articles by advanced second language learners (1997) (39)
Correlates of coronary blood flow before and after percutaneous coronary intervention and their relationship to angiographic and clinical outcomes in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. (2002) (39)
Severity of heart failure, treatments, and outcomes after fibrinolysis in patients with ST-elevation myocardial infarction. (2004) (39)
Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51). (2013) (39)
Prior aspirin use and outcomes in acute coronary syndromes. (2010) (38)
Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel. (2007) (38)
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). (2008) (38)
Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: Impact of age (A Meta-Analysis of a Decade of Trials) (2006) (38)
When 'digoxin use' is not the same as 'digoxin use': lessons from the AFFIRM trial. (2013) (38)
Cost-effectiveness of distal embolic protection for patients undergoing percutaneous intervention of saphenous vein bypass grafts: results from the SAFER trial. (2004) (37)
Sample size formulae for two-stage randomized trials with survival outcomes. (2011) (37)
Variable Selection for Qualitative Interactions in Personalized Medicine While Controlling the Family-Wise Error Rate (2011) (37)
Examining clinical judgment in an adaptive intervention design: The fast track program. (2006) (37)
Treatment delay in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a key process analysis of patient and program factors. (2008) (37)
Implications of family history of myocardial infarction in young women. (2007) (37)
Statistical Inference in Dynamic Treatment Regimes (2010) (37)
Action Centered Contextual Bandits (2017) (36)
Rejoinder to discussion of ``On Profile Likelihood''. (2000) (36)
Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. (2005) (36)
Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction; insights from TIMI 14 and InTIME-II. (2002) (36)
Toward Increasing Engagement in Substance Use Data Collection: Development of the Substance Abuse Research Assistant App and Protocol for a Microrandomized Trial Using Adolescents and Emerging Adults (2018) (36)
SARA: a mobile app to engage users in health data collection (2017) (36)
Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16 (2008) (36)
Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome. (2006) (35)
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial. (2020) (35)
Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trial. (2014) (35)
Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70 (2022) (35)
Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes (2012) (35)
Self‐Acupressure for Older Adults With Symptomatic Knee Osteoarthritis: A Randomized Controlled Trial (2018) (35)
Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTion against post-PCI microvascular dysfu (2006) (34)
Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2°P-TIMI 50 Trial. (2016) (34)
Optimizing Digital Integrated Care via Micro‐Randomized Trials (2018) (34)
Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease. (2019) (34)
Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial. (2006) (34)
Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. (2004) (34)
Current Status Regression (1999) (34)
Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study). (2009) (34)
Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina (2006) (33)
Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome (2018) (33)
Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial. (2005) (33)
Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data (2019) (33)
Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50 (2015) (33)
Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: results from the Thrombolysis in Myocardial Infarction (TIMI) 11B and Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) studies. (2003) (33)
Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction. (2004) (32)
New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial. (2014) (32)
Estimating time-varying causal excursion effect in mobile health with binary outcomes. (2019) (31)
Association of lipoprotein-associated phospholipase A2 mass and activity with coronary and aortic atherosclerosis: findings from the Dallas Heart Study. (2008) (31)
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58 (2020) (31)
Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial (2019) (31)
Evaluation of the diagnostic performance of current and next-generation assays for cardiac troponin I in the BWH-TIMI ED Chest Pain Study (2013) (31)
DAPAGLIFLOZIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND PRIOR MYOCARDIAL INFARCTION: A SUB-ANALYSIS FROM DECLARE TIMI-58 TRIAL (2019) (31)
Diagnostic and prognostic value of ambulatory ECG (Holter) monitoring in patients with coronary heart disease: a review (2007) (31)
Association of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention (A REPLACE-2 analysis). (2007) (31)
Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial (2014) (31)
Variable Selection for Optimal Decision Making (2007) (31)
Timing of angiography and revascularization in acute coronary syndromes: an analysis of the TACTICS-TIMI-18 trial. (2004) (30)
Factors contributing to physical activity in a chronic low back pain clinical sample: A comprehensive analysis using continuous ambulatory monitoring (2011) (30)
Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators. (1999) (30)
Methodologic and Clinical Validation of the TIMI Myocardial Perfusion Grade in Acute Myocardial Infarction (2002) (29)
Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis (2008) (29)
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease (2022) (29)
PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes (2015) (29)
Clinical, procedural, and pharmacologic correlates of acute and subacute stent thrombosis: results of a multicenter case-control study with 145 thrombosis events. (2008) (29)
Designing adaptive intensive interventions using methods from engineering. (2014) (29)
Association of Epicardial and Tissue-Level Reperfusion with Left Ventricular End-Diastolic Pressures in ST-Elevation Myocardial Infarction (2004) (29)
Assessing the Total Effect of Time-Varying Predictors in Prevention Research (2006) (28)
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. (2022) (28)
Semiparametric Mixtures in Case-Control Studies (2001) (28)
Degree of residual stenosis in the culprit coronary artery after thrombolytic administration (Thrombolysis In Myocardial Infarction [TIMI] trials). (2000) (27)
Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: Observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS–TIMI 16) trial (2005) (27)
Prognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classification. (2002) (27)
Mobile Health Technology Evaluation (2016) (27)
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial. (2020) (27)
Association of a History of Systemic Hypertension With Mortality, Thrombotic, and Bleeding Complications Following Non‐ST‐Segment Elevation Acute Coronary Syndrome (2006) (27)
Micro-randomized trials & mHealth (2015) (26)
Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial. (2015) (26)
Prognostic Evaluation of Catalytic Iron in Patients With Acute Coronary Syndromes (2013) (26)
Acupressure for persistent cancer-related fatigue in breast cancer survivors (AcuCrft): a study protocol for a randomized controlled trial (2012) (26)
Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. (2019) (26)
From Markers to Interventions: The Case of Just-in-Time Stress Intervention (2017) (26)
A multiple imputation strategy for sequential multiple assignment randomized trials. (2017) (26)
The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy. (2016) (25)
SMARTer discontinuation trial designs for developing an adaptive treatment strategy. (2012) (25)
Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from DECLARE‐TIMI 58 (2020) (25)
An Actor-Critic Contextual Bandit Algorithm for Personalized Interventions using Mobile Devices (2014) (25)
The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies. (2004) (25)
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58 (2021) (24)
Personalized HeartSteps (2020) (24)
Just-in-Time but Not Too Much: Determining Treatment Timing in Mobile Health (2018) (24)
Association of the Fibonacci Cascade with the distribution of coronary artery lesions responsible for ST-segment elevation myocardial infarction. (2003) (24)
Model-Free Monte Carlo-like Policy Evaluation (2010) (24)
Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST-elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18. (2004) (24)
Optimizing delivery of a behavioral pain intervention in cancer patients using a sequential multiple assignment randomized trial SMART. (2017) (24)
Abstract 16612: Efficacy and Safety of Edoxaban for the Management of Elderly Patients With Atrial Fibrillation: Engage AF-TIMI 48 (2014) (24)
Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. (2006) (23)
Developments in Mobile Health Just-in-Time Adaptive Interventions for Addiction Science (2020) (23)
Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial. (2007) (23)
Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration. (2002) (23)
Intensive lipid lowering with atorvastatin in coronary disease. (2005) (23)
Fatigability in osteoarthritis: effects of an activity bout on subsequent symptoms and activity. (2012) (23)
Mode and timing of treatment failure (recurrent ischemic events) after hospital admission for non-ST segment elevation acute coronary syndromes. (2002) (23)
Just-in-Time but Not Too Much (2018) (23)
Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy (2006) (23)
Early invasive strategy improves outcomes in patients with acute coronary syndrome with previous coronary artery bypass graft surgery: a report from TACTICS-TIMI 18. (2006) (23)
Benchmarking participation of Canadian university health sciences librarians in systematic reviews. (2015) (23)
A Batch, Off-Policy, Actor-Critic Algorithm for Optimizing the Average Reward (2016) (23)
Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28). (2006) (23)
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials (2022) (23)
Underutilization of evidence-based medications in acute ST elevation myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 9 Registry. (2002) (23)
Abciximab improves both epicardial flow and myocardial reperfusion in ST elevation myocardial infarction: a TIMI 14 analysis (1999) (22)
Quantitative Comparison of Coronary Artery Flow and Myocardial Perfusion in Patients with Acute Myocardial Infarction in the Presence and Absence of Recent Cocaine Use (2002) (22)
Clinical characteristics, vascular function, and inflammation in women with angina in the absence of coronary atherosclerosis: the Dallas Heart Study. (2011) (22)
Evaluation of the diagnostic performance of heart-type fatty acid binding protein in the BWH-TIMI ED chest pain study (2013) (22)
An analysis for menstrual data with time-varying covariates. (1995) (22)
Administration of intracoronary eptifibatide during ST-elevation myocardial infarction. (2005) (22)
Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world. (2012) (22)
Impact of Self-Acupressure on Co-Occurring Symptoms in Cancer Survivors (2018) (22)
Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction. (2008) (21)
Investigating the Impact of Selection Bias in Dose-Response Analyses of Preventive Interventions (2010) (21)
Racial disparity in clinical outcomes following primary percutaneous coronary intervention for ST elevation myocardial infarction: influence of process of care. (2007) (21)
Likelihood Inference in the Errors-in-Variables Model (1996) (21)
Optimizing mHealth Interventions with a Bandit (2019) (21)
Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE‐TIMI 58 study (2020) (21)
Projected partial likelihood and its application to longitudinal data (1995) (20)
Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the MERLIN‐TIMI 36 Trial (2015) (20)
Activity pacing: what are we measuring and how does that relate to intervention? (2010) (20)
IntelligentPooling: practical Thompson sampling for mHealth (2020) (20)
Predictors of coronary artery disease in patients with left bundle branch block undergoing coronary angiography. (2006) (20)
First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trial. (2017) (20)
Subgroups Analysis when Treatment and Moderators are Time-varying (2013) (20)
Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36 (2015) (20)
The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial (2015) (20)
An Individualized, Data-Driven Digital Approach for Precision Behavior Change (2020) (20)
Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. (2021) (20)
The microrandomized trial for developing digital interventions: Experimental design and data analysis considerations. (2021) (19)
Clinical Features, Use of Evidence‐Based Therapies, and Cardiovascular Outcomes Among Patients With Chronic Kidney Disease Following Non–ST‐Elevation Acute Coronary Syndrome (2014) (19)
Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. (2021) (19)
Impact of gender on angiographic and clinical outcomes after fibrinolytic therapy in acute myocardial infarction. (2002) (19)
High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial. (2017) (19)
Baseline platelet count and clinical outcome in acute coronary syndrome. (2012) (19)
Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. (2020) (19)
Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)‐TIMI 50 (2016) (19)
Inferring bounds on the performance of a control policy from a sample of trajectories (2009) (19)
Diagnostic evaluation of the MRP-8/14 for the emergency assessment of chest pain (2012) (19)
Just-in-Time Adaptive Interventions for Suicide Prevention: Promise, Challenges, and Future Directions (2021) (18)
A multiple imputation strategy for sequential multiple assignment randomized trials (2014) (18)
Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy). (2004) (18)
Myonecrosis following stent placement: Association between impaired TIMI myocardial perfusion grade and MRI visualization of microinfarction (2004) (18)
Rivaroxaban in Patients Stabilized after a ST-Elevation Myocardial Infarction: Results from the ATLAS ACS 2-TIMI 51 Trial. (2013) (18)
Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58 (2021) (18)
Developing an Adaptive Mobile Intervention to Address Risky Substance Use Among Adolescents and Emerging Adults: Usability Study (2021) (18)
Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy (2013) (18)
Benefits of pharmacological facilitation with glycoprotein IIb-IIIa inhibitors in diabetic patients undergoing primary angioplasty for STEMI. A subanalysis of the EGYPT cooperation (2009) (18)
Two‐Level Proportional Hazards Models (2002) (17)
Ambulatory Monitoring as a Measure of Disability in Chronic Low Back Pain Populations (2011) (17)
Time‐varying effect moderation using the structural nested mean model: estimation using inverse‐weighted regression with residuals (2014) (17)
Impact of aprotinin on adverse clinical outcomes and mortality up to 12 years in a registry of 3,337 patients. (2008) (17)
Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial. (2020) (17)
THE STRATIFIED MICRO-RANDOMIZED TRIAL DESIGN: SAMPLE SIZE CONSIDERATIONS FOR TESTING NESTED CAUSAL EFFECTS OF TIME-VARYING TREATMENTS. (2017) (17)
Linear mixed models with endogenous covariates: modeling sequential treatment effects with application to a mobile health study. (2019) (17)
Association of an activated clotting time < or =250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy). (2003) (16)
Towards Min Max Generalization in Reinforcement Learning (2010) (16)
Program evaluation of a model to integrate internationally educated health professionals into clinical practice (2013) (16)
Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial (2020) (16)
Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial). (2007) (16)
Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial (2018) (16)
A Cautious Approach to Generalization in Reinforcement Learning (2010) (16)
Happy birthday European Heart Journal: in 30 years, from Cinderella to centre stage. (2010) (16)
PERIOPERATIVE ADVERSE OUTCOMES IN PATIENTS WITH ATRIAL FIBRILLATION TAKING EDOXABAN OR WARFARIN: ANALYSIS OF THE ENGAGE AF-TIMI 48 TRIAL (2015) (15)
REDUCTION IN ISCHEMIC EVENTS WITH TICAGRELOR IN DIABETIC PATIENTS FROM THE PEGASUS-TIMI 54 TRIAL (2016) (15)
Single lead ST-segment recovery: a simple, reliable measure of successful fibrinolysis after acute myocardial infarction. (2004) (15)
Self-administered Acupressure for Persistent Cancer-related Fatigue: Fidelity Considerations. (2015) (15)
Vorapaxar in Patients With Diabetes and Prior MI: Findings from the TRA 2°P-TIMI 50 Trial (2015) (15)
iSurvive: An Interpretable, Event-time Prediction Model for mHealth (2017) (15)
Statistical Inference with M-Estimators on Adaptively Collected Data (2021) (15)
Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study. (2008) (15)
Artificial intelligence decision-making in mobile health (2019) (15)
A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. (2008) (15)
Standardized Effect Sizes for Preventive Mobile Health Interventions in Micro-randomized Trials (2017) (15)
Impairment of myocardial perfusion in both culprit and nonculprit arteries in acute myocardial infarction: a LIMIT AMI substudy. (2003) (15)
Engagement in digital interventions. (2022) (15)
ewrapper: operationalizing engagement strategies in mHealth (2017) (15)
Cardiovascular and renal benefits of dapagliflozin in patients with short and long‐standing type 2 diabetes: Analysis from the DECLARE‐TIMI 58 trial (2020) (15)
Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudy. (2001) (14)
Distribution of traditional and novel risk factors and their relation to subsequent cardiovascular events in patients with acute coronary syndromes (from the PROVE IT-TIMI 22 trial). (2010) (14)
On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study). (2015) (14)
Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleed. (2007) (14)
Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients. (2005) (14)
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. (2021) (14)
Evaluation of coronary artery calcium screening strategies focused on risk categories: the Dallas Heart Study. (2009) (14)
Self-Administered Acupressure for Chronic Low Back Pain: A Randomized Controlled Pilot Trial. (2019) (14)
Stress Prevention and Mindfulness: A Psychoeducational and Support Group for Teachers (2016) (14)
Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy. (2006) (14)
Predictors of mortality, coronary angiography, and revascularization in unstable angina pectoris and acute non-ST elevation myocardial infarction (the TIMI III Registry). (2002) (13)
Practical Considerations for Data Collection and Management in Mobile Health Micro-randomized Trials (2018) (13)
Center of Excellence for Mobile Sensor Data-to-Knowledge (MD2K). (2017) (13)
Active Learning for Developing Personalized Treatment (2011) (13)
Effect of Aromatase Inhibitor Therapy on Sleep and Activity Patterns in Early‐stage Breast Cancer (2017) (13)
Design Lessons from a Micro-Randomized Pilot Study in Mobile Health (2017) (13)
Mobile Health: Sensors, Analytic Methods, and Applications (2017) (13)
Translating strategies for promoting engagement in mobile health: A proof-of-concept microrandomized trial. (2021) (13)
Effects of cognitive task demands on subsequent symptoms and activity in adults with symptomatic osteoarthritis. (2013) (13)
Global impairment of coronary blood flow in the setting of acute coronary syndromes (a RESTORE substudy)1 (2000) (13)
Are we appropriately triaging patients with unstable angina? (2005) (13)
Effect of tailored activity pacing on self-perceived joint stiffness in adults with knee or hip osteoarthritis. (2012) (13)
Power-Constrained Bandits (2020) (12)
Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: Results of the TIMI 31 trial (2006) (12)
Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization. (2020) (12)
A study of career values by generation and gender (2000) (12)
Global impairment of coronary blood flow in the setting of acute coronary syndromes (a RESTORE substudy). Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. (2000) (12)
SMART Design Issues and the Consideration of Opposing Outcomes: Discussion of "Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer" by by Wang, Rotnitzky, Lin, Millikan, and Thall. (2012) (12)
Association of angiographic perfusion score following percutaneous coronary intervention for ST-elevation myocardial infarction with left ventricular remodeling at 6 weeks in GRACIA-2 (2009) (12)
Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease. (2016) (12)
Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome. (2018) (12)
Abstract 19119: Concomitant Use of Antiplatelet Therapy with Edoxaban or Warfarin in Patients with Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial (2014) (11)
Effect of rescue or adjunctive percutaneous coronary intervention of the culprit artery after fibrinolytic administration on epicardial flow in nonculprit arteries. (2004) (11)
Active learning for personalizing treatment (2011) (11)
Abstract 3288: Association of Treatment with Non-Steroidal Anti-Inflammatory Agents (NSAIDS) on Study Entry with 30 Day Adverse Outcomes Among ST Elevation MI (STEMI) Patients Treated with a Fibrinolytic Agent. An EXTRACT-TIMI 25 Analysis (2006) (11)
One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trial. (2010) (11)
Static versus dynamic splinting for proximal interphalangeal joint pyrocarbon implant arthroplasty: a comparison of current and historical cohorts. (2011) (11)
Impact of contrast agent type (ionic versus nonionic) used for coronary angiography on angiographic, electrocardiographic, and clinical outcomes following thrombolytic administration in acute myocardial infarction (2001) (10)
Mobile Health (2017) (10)
Diagnostic Performance of Copeptin in Patients With Acute Nontraumatic Chest Pain: BWH‐TIMI ED Chest Pain Study (2014) (10)
Does fall history influence residential adjustments? (2011) (10)
Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. (2006) (10)
Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. (2021) (10)
Infarct-related coronary artery patency and medication use prior to ST-segment elevation myocardial infarction. (2006) (10)
Intelligent Pooling in Thompson Sampling for Rapid Personalization in Mobile Health (2019) (9)
Rejoinder of “Dynamic treatment regimes: Technical challenges and applications” (2014) (9)
The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus (2021) (9)
Microrandomized trials for promoting engagement in mobile health data collection: Adolescent/young adult oral chemotherapy adherence as an example. (2020) (9)
Abstract 1515: Outcomes of Patients With Acute Coronary Syndromes and Prior Coronary Artery Bypass Grafting. Results From the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE-IT-TIMI 22) and the Aggrastat to Zocor (A to Z) trials. (2007) (9)
Time for contrast material to traverse the epicardial artery and the myocardium in ST-segment elevation acute myocardial infarction versus unstable angina pectoris/non-ST-elevation acute myocardial infarction. (2003) (9)
Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT (2022) (9)
Missing Data and Uncertainty in Batch Reinforcement Learning (2008) (9)
Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trial. (2006) (9)
ReVibe: A Context-assisted Evening Recall Approach to Improve Self-report Adherence (2019) (9)
The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes. (2008) (9)
Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. (2004) (9)
Precordial ST-Segment Depression in Inferior Myocardial Infarction is Associated with Slow Flow in the Non-Culprit Left Anterior Descending Artery (2002) (8)
Generating Informative Trajectories by using Bounds on the Return of Control Policies (2010) (8)
Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial. (2005) (8)
Aging, Fatigue, and Fatigability: Implications for Occupational and Physical Therapists (2014) (8)
Adaptive treatment strategies (2008) (8)
Knee and Hip Osteoarthritis Management: A Review of Current and Emerging Non-Pharmacological Approaches (2016) (8)
EFFICACY AND SAFETY OF EDOXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AND ACTIVE MALIGNANCY: AN ANALYSIS OF ENGAGE AF – TIMI 48 RANDOMIZED CLINICAL TRIAL (2017) (8)
Developing adaptive treatment strategies in substance abuse (2007) (8)
Optimizing an Acceptance and Commitment Therapy Microintervention Via a Mobile App With Two Cohorts: Protocol for Micro-Randomized Trials (2020) (8)
Abstract 20183: Atherothrombotic Risk Stratification and Magnitude of Benefit of Evolocumab in FOURIER (2017) (8)
Feasibility of a Randomized Controlled Trial of Self-Administered Acupressure for Symptom Management in Older Adults with Knee Osteoarthritis. (2016) (8)
Conducting Successful Virtual Meetings While Managing COVID Fatigue. (2021) (8)
Innovative Health Care Delivery: The Scientific and Regulatory Challenges in Designing mHealth Interventions. (2021) (8)
Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis (2011) (8)
Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction. (2004) (8)
Treatment and outcomes of eastern Europeans with coronary syndromes in OPUS-TIMI 16. (2005) (8)
Impact of saphenous vein graft radiographic markers on clinical events and angiographic parameters. (2008) (8)
Are statins being underdosed in clinical practice? Data from TACTICS-TIMI 18. (2005) (8)
Can we replace the 90-minute thrombolysis in myocardial infarction (TIMI) flow grades with those at 60 minutes as a primary end point in thrombolytic trials? TIMI Study Group. (2001) (8)
Comparison of errors in estimating weight and in dosing of single-bolus tenecteplase with tissue plasminogen activator (TIMI 10B and ASSENT I). (2002) (8)
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. (2022) (7)
Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. (2004) (7)
BASELINE LDL-C AND CLINICAL OUTCOMES WITH ADDITION OF EZETIMIBE TO STATIN IN 18,144 PATIENTS POST ACS (2015) (7)
Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects　- A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. (2021) (7)
TIMI risk index and the benefit of enoxaparin in patients with ST-elevation myocardial infarction. (2007) (7)
C-reactive protein and cardiovascular outcomes in smokers versus nonsmokers in non-ST-elevation acute coronary syndrome (from the TACTICS-TIMI 18 trial). (2005) (7)
MLE in the proportional odds model (1996) (7)
Abstract 13798: Effect of Ranolazine on Atrial Fibrillation Among Patients with Non-ST Elevation Acute Coronary Syndromes (NSTEACS) - Observations from the MERLIN-TIMI 36 Trial (2011) (7)
Drug Use Prevention Data, Missed Assessments and Survival Analysis. (1998) (7)
Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function (2018) (6)
Statistical Inference with M-Estimators on Bandit Data (2021) (6)
Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction. (2010) (6)
Linear mixed models under endogeneity: modeling sequential treatment effects with application to a mobile health study (2019) (6)
Abstract 3994: Pharmacodynamic Assessment of Platelet Inhibition by Prasugrel versus Clopidogrel in the TRITON-TIMI 38 Trial (2008) (6)
Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial (2021) (6)
Preventive cardiologyAbstractRace and Gender Differences in C-Reactive Protein Levels (2005) (6)
It's Not Just a Needlestick: Exploring Phlebotomists' Knowledge, Training, and Use of Comfort Measures in Pediatric Care to Improve the Patient Experience. (2019) (6)
Budgeted Learning for Developing Personalized Treatment (2014) (6)
Impact of injections during diagnostic coronary arteriography on coronary patency in the setting of acute myocardial infarction from the TIMI trials. Thrombolysis In Myocardial Infarction. (2000) (6)
Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50). (2016) (6)
Abstract 14508: Vorapaxar for Secondary Prevention after Myocardial Infarction According to Aspirin Dose - Insights from the TRA2{degrees}P-TIMI 50 Trial (2012) (6)
Design and evaluation of adaptive preventive interventions (2001) (6)
Critical pathway for acute ST-segment elevation myocardial infarction: estimating its potential impact in the TIMI 9 Registry. (2002) (6)
Mentor Satisfaction Using a New Model of Clinical Education (2014) (6)
Information Commonly Unreported in Intervention Effectiveness Studies (2012) (6)
Comparison of Nurse Mentor and Instructor Evaluation of Clinical Performance (2014) (6)
Assessing the effect of publication of clinical guidelines on the management of unstable angina and non-ST elevation myocardial infarction in the TIMI III (1990-1993) and the GUARANTEE (1995-1996) Registries. (2002) (6)
A central limit theorem for local martingales with applications to the analysis of longitudinal data (1995) (6)
Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial (2018) (6)
The Micro-Randomized Trial for Developing Digital Interventions: Data Analysis Methods (2020) (5)
Computing bounds for kernel-based policy evaluation in reinforcement learning (2010) (5)
The mobile assistance for regulating smoking (MARS) micro-randomized trial design protocol. (2021) (5)
Semiparametric Likelihood Ratio (1996) (5)
DISCHARGE ASPIRIN DOSE AND CLINICAL OUTCOMES IN PATIENTS WITH ACS: AN ANALYSIS FROM THE TRITON-TIMI 38 STUDY (2012) (5)
Angiographic and clinical characteristics associated with the development of Q-wave and non-Q-wave myocardial infarction in the thrombolysis in myocardial infarction (TIMI) 14 trial. (2003) (5)
The Effect of a Disease Management Algorithm and Dedicated Postacute Coronary Syndrome Clinic on Achievement of Guideline Compliance (2008) (5)
A risk score for predicting coronary artery disease in women with angina pectoris and abnormal stress test finding. (2013) (5)
Just-in-time adaptive interventions (2014) (5)
Abstract 19694: Reduction in Non-hemorrhagic Stroke With Ezetimibe/Simvastatin Compared With Simvastatin Alone in the IMPROVE-IT Trial (2015) (5)
Small Sample Inference for Generalization Error in Classification Using the CUD Bound (2008) (5)
Association of chronic spinal pain with diet quality (2020) (5)
Multilevel survival analysis (1996) (5)
Abstract 18595: Efficacy of Vorapaxar is not Modified by Thienopyridine Therapy: Results from TRA 2°P-TIMI 50 Trial (2012) (5)
Exploring innovative methods to evaluate the efficacy and safety of mobile health (2013) (5)
Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58. (2022) (5)
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial (2022) (5)
Outcome of patients with acute coronary syndrome admitted to hospitals with or without onsite cardiac catheterization laboratory: a TACTICS-TIMI 18 substudy. (2002) (5)
Abstract 15100: Reduction in Total Cardiovascular Events With the PCSK9 Inhibitor Evolocumab in Patients With Cardiovascular Disease in the FOURIER Trial (2017) (5)
Structural nested models (2010) (5)
The Micro-Randomized Trial for Developing Digital Interventions: Experimental Design Considerations (2020) (4)
Intensive antiplatelet therapy for reduction of ischaemic events – Authors' reply (2008) (4)
Abstract 2221: Triple Therapy (TTx): ASA, Thienopyridine and Oral Anticoagulation (OA) Therapy Following ST Elevation Myocardial Infarction (STEMI): Is it Safe? (2007) (4)
Patterns of Long‐term Thienopyridine Therapy and Outcomes in Patients With Acute Coronary Syndrome Treated With Coronary Stenting: Observations From the TIMI‐38 Coronary Stent Registry (2014) (4)
Abstract 13152: A Net Clinical Outcome Analysis Comparing Fatal or Irreversible Ischemic and Bleeding Events in ATLAS ACS 2 - TIMI 51 (2012) (4)
Association of lesion complexity following fibrinolytic administration with mortality in ST-elevation myocardial infarction. (2004) (4)
Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention (2022) (4)
TIMING AND CLINICAL SETTING OF CARDIOVASCULAR DEATH OR MYOCARDIAL INFARCTION FOLLOWING PCI FOR ACS – OBSERVATIONS FROM THE TRITON-TIMI 38 TRIAL (2012) (4)
Combination therapy with clopidogrel and proton-pump inhibitors – Authors' reply (2010) (4)
Association of culprit lesion calcium with angiographic and clinical outcomes in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy. (2005) (4)
Unfortunate impact of age on the management and outcomes of unstable angina and non-ST elevation myocardial infarction (The GUARANTEE Registry). (2005) (4)
FROM THE DESK OF THE EDITOR AND ASSOCIATE EDITOR Information Commonly Unreported in Intervention Effectiveness Studies (2015) (4)
Translating Behavioral Theory into Technological Interventions: Case Study of an mHealth App to Increase Self-reporting of Substance-Use Related Data (2020) (4)
Assessing Confidence in Policies Learned from Sequential Randomized Trials (2009) (4)
ReVibe (2019) (4)
SAS PROC QLEARN Users’ Guide (Version 1.0) (2012) (4)
Statistical Inference After Adaptive Sampling in Non-Markovian Environments (2022) (4)
Designing Reinforcement Learning Algorithms for Digital Interventions: Pre-Implementation Guidelines (2022) (4)
Correlation between ST resolution and angiographic findings in ST elevation myocardial infarction (2002) (3)
Impact of iodinated contrast injections on percent diameter coronary arterial stenosis and implications for trials of intracoronary pharmacotherapies in patients with ST-elevation myocardial infarction. (2007) (3)
Abstract 16714: Characterization of Types and Sizes of Myocardial Infarction Reduced With Evolocumab in FOURIER (2017) (3)
Abstract 11748: Edoxaban versus Warfarin in Patients at Increased Risk of Falling - A Subgroup Analysis of the ENGAGE AF-TIMI 48 Trial (2015) (3)
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial (2022) (3)
RIVAROXABAN REDUCES SPONTANEOUS AND LARGE MYOCARDIAL INFARCTIONS: FINDINGS FROM THE ATLAS ACS 2 – TIMI 51 TRIAL (2013) (3)
Rapidly Personalizing Mobile Health Treatment Policies with Limited Data (2020) (3)
Micro‐Randomized Trial (2018) (3)
Addressing the Computational Challenges of Personalized Medicine (Dagstuhl Seminar 17472) (2017) (3)
Examining Moderated Effects of Additional Adolescent Substance Use Treatment (2012) (3)
Causal inference for longitudinal data (2003) (3)
Elevated C Reactive Protein (CRP) is associated with a higher risk of thrombotic occlusion and poorer flow following percutaneous coronary intervention in patients with acute coronary syndromes: a TACTICS TIMI 18 angiographic substudy (2002) (3)
PCSK9 INHIBITION AND AORTIC STENOSIS IN THE FOURIER TRIAL (2020) (3)
Prasugrel STEMI subgroup analysis – Authors' reply (2009) (3)
Adaptive Intervention Designs in Substance Use Prevention (2019) (3)
Angiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction. (2005) (3)
LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease (2021) (3)
EFFECTS OF DAPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS BODY MASS INDEX CATEGORIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN THE DECLARE TIMI 58 TRIAL (2020) (3)
Erratum to: Subgroups Analysis when Treatment and Moderators are Time-varying (2013) (3)
Off the shelf or recalibrate? customizing a risk index for assessing mortality. (2003) (3)
E-cient A-Learning for Dynamic Treatment Regimes: A Handout (2005) (2)
How can fatigue be addressed in individuals with systemic sclerosis? (2020) (2)
Comment (2012) (2)
Edoxaban versus Warfarin in Patients with Atrial Fibrillation in Relation to the Risk of Stroke: A Secondary Analysis of the ENGAGE AF-TIMI 48 Study. (2021) (2)
Increased risk of adverse outcomes with proximal culprit artery lesions in acute myocardial infarction (2003) (2)
RELATIONSHIP BETWEEN DOSE, ANTI-FACTOR XA ACTIVITY, AND OUTCOMES IN PATIENTS RANDOMIZED TO EDOXABAN IN THE ENGAGE AF-TIMI 48 TRIAL (2014) (2)
The benefit of an early invasive strategy in women versus men with non-ST-elevation acute coronary syndromes: A collaborative meta-analysis of randomized trials (2007) (2)
Erratum: Comparison of a phased experimental approach and a single randomized clinical trial for developing multicomponent behavioural interventions (Clinical Trials (2009) vol. 6 (5-15) 10.1177/1740774508100973) (2009) (2)
Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction. (2005) (2)
Prognostic Performance of Multiple Biomarkers in Patients with Non-ST Elevation Acute Coronary Syndrome: Analysis from MERLIN-TIMI 36 (2014) (2)
Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment–Elevation Myocardial Infarction: Results of REAL-TIMI 63B (2022) (2)
VORAPAXAR REDUCES PERIPHERAL REVASCULARIZATION REGARDLESS OF THE NUMBER OF DISEASED TERRITORIES: INSIGHTS FROM THE TRA2P–TIMI 50 TRIAL (2013) (2)
Women's Health Study: low dose aspirin in primary prevention. (2005) (2)
Discussions: Principal Stratification and Missing Inputs (2007) (2)
Abstract 11382: The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial (2013) (2)
The Latent Curriculum: Breaking Conceptual Barriers to Information Architecture (2012) (2)
Insights into the Pathophysiology of Acute Ischemic Syndromes Using the TIMI Flow Grade, TIMI Frame Count, and TIMI Myocardial Perfusion Grade (2003) (2)
RELATIONSHIP OF HEART RATE AND CARDIOVASCULAR EVENTS IN PATIENTS AFTER ACUTE CORONARY SYNDROMES: AN ANALYSIS FROM THE PROVE-IT TIMI 22 TRIAL (2010) (2)
Active exploration by searching for experiments that falsify the computed control policy (2011) (2)
Estimating causal effects with optimization-based methods: A review and empirical comparison (2022) (2)
MLE IN THE PROPORTIONAL ODDS MODELBY (2)
Fast Physical Activity Suggestions: Efficient Hyperparameter Learning in Mobile Health (2020) (2)
Ignorable dropout in longitudinal studies (1998) (2)
Abstract 18928: Vorapaxar Reduces Coronary Stent Thrombosis: Results From the TRA2P-TIMI 50 Trial (2013) (2)
Abstract 19221: Rates of Arterial Revascularization in Patients Treated with Vorapaxar vs. Placebo in the TRA 2{degrees}P-TIMI 50 Trial (2012) (2)
SARA - Substance Abuse Research Assistant (2017) (2)
Abstract 9309: Benefit of Prasugrel in ST-Elevation Myocardial Infarction According to Timing of Percutaneous Coronary Intervention: Insight from the TRITON-TIMI 38 Study (2011) (2)
Understanding Adolescent and Young Adult 6-Mercaptopurine Adherence and mHealth Engagement During Cancer Treatment: Protocol for Ecological Momentary Assessment (2021) (2)
Abstract 2860: Does the Efficacy of the Low-Molecular Weight Heparin Enoxaparin over Unfractionated Heparin Balance the Safety Profile in ST-elevation Myocardial Infarction? A Meta-Analysis of 27,000 Patients (2006) (2)
Ischemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full and half-dose Edoxaban vs. Warfarin: insights from ENGAGE AF-TIMI 48. (2021) (2)
Patients With ST-Segment Elevation Myocardial Infarction U-Shaped Relationship of Blood Glucose With Adverse Outcomes Among (2011) (2)
PROGNOSTIC PERFORMANCE OF A SINGLE-MOLECULE HIGH-SENSITIVITY CARDIAC TROPONIN ASSAY AFTER NON-ST ELEVATION ACUTE CORONARY SYNDROME: ANALYSIS FROM MERLIN-TIMI 36 (2012) (2)
Cost-effectiveness of coronary stenting and abciximab for patients with AMI: Results from the CADILLAC trial (2002) (2)
Safety of adjunctive glycoprotein IIb/IIIa blockade during rescue/early percutaneous coronary intervention following full-dose fibrinolytic therapy for acute myocardial infarction (2003) (2)
Building a Coaching Culture-The Roles of Coaches, Mentors, and Sponsors. (2021) (2)
Abstract 11559: Determination of Cardiac Troponin with a Single-Molecule High-Sensitivity Assay and Outcomes in Patients with Stable Coronary Artery Disease: Analysis from PROVE IT-TIMI 22 (2012) (2)
Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE (2023) (2)
Rejoinder: 'Estimating time-varying causal excursion effects in mobile health with binary outcomes'. (2021) (2)
Coronary Stent Thrombosis With Vorapaxar Versus Placebo (2015) (2)
Comparing treatment policies with assistance from the structural nested mean model (2016) (2)
Coronary Heart Disease Clinical Features and Outcomes of Women With Unstable Ischemic Heart Disease (2010) (2)
Abstract 15670: Relationship Between Baseline Cardiac Biomarkers and Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58 (2019) (2)
Decision-Making During Percutaneous Coronary Intervention Guided by Optical Coherence Tomography: Insights From the LightLab Initiative (2022) (2)
Abstract 17121: Reduction in Total Cardiovascular Events With Long-term Use of Ticagrelor in Patients With Prior Myocardial Infarction in the PEGASUS-TIMI 54 Trial (2015) (2)
Abstract 17455: Pharmacodynamic Response to Clopidogrel in Men versus Women: Insights from the PRINCIPLE-TIMI 44 Trial (2012) (2)
Myocardial Infarction The Prognostic Value of Serum Myoglobin in Patients With Non – ST-Segment Elevation Acute Coronary Syndromes Results From the TIMI 11 B and TACTICS-TIMI 18 Studies (2016) (2)
Maximum likelihood estimation of the structural nested mean model using SAS PROC NLP: With application to the study of time-varying moderators of the effect of weight change on quality of life (2010) (2)
Using Sequential , Multiple Assignment , Randomized Trial ( SMART ) Designs to Build Individualized Treatment Sequences (2011) (2)
Effect of Darapladib onMajor Coronary Events After an Acute Coronary Syndrome The SOLID-TIMI 52 Randomized Clinical Trial (2014) (2)
MEDIATION ANALYSIS FOR DAPAGLIFLOZIN AND THE REDUCTION IN HOSPITALIZATION FOR HEART FAILURE IN DECLARE-TIMI 58 (2021) (1)
STATIN INTENSITY AND OUTCOME IN PATIENTS WITH PERIPHERAL ARTERY DISEASE: INSIGHTS FROM THE TRA2P-TIMI 50 TRIAL (2015) (1)
Multimarker Risk Strati fi cation in Patients With Acute Myocardial Infarction (2016) (1)
GROWTH DIFFERENTIATION FACTOR-15 LEVEL PREDICTS RECURRENT CARDIOVASCULAR EVENTS IN PATIENTS WITH AN ACUTE CORONARY SYNDROME IN MERLIN-TIMI 36 (2014) (1)
PROGNOSTIC VALUE OF HIGH-SENSITIVITY CRP FOR CARDIOVASCULAR OUTCOMES IN TRA 2°P-TIMI 50 (2013) (1)
Abstract 2453: Effect of Ranolazine on Hemoglobin A1c in the MERLIN-TIMI 36 Randomized Controlled Trial (2007) (1)
Elevated serum myoglobin is associated with increased long-term mortality, independent of cardiac troponin I, electrocardiographic variables, and other baseline variables: combined analyses from TIMI 11B and TACTICS/TIMI 18 (2002) (1)
TCT-719 Effects of ranolazine in patients with acute coronary syndrome and stable angina according to whether they undergo percutaneous coronary intervention: Observations from the MERLIN-TIMI 36 Trial (2012) (1)
Martin/Hopkins Estimation, Friedewald and Beta-Quantification of LDL-C in Patients in FOURIER* (2018) (1)
Off-Label Use of Ondansetron In Hospitalized Medical Patients: Prevalence, Patterns, and Predictors (2013) (1)
Reply: Personalize and Optimize Lipid-Lowering Therapies. (2016) (1)
Outcomes in Patients With Acute Coronary Syndromes Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and (2003) (1)
PROGNOSTIC PERFORMANCE OF SERIAL HIGH SENSITIVITY CARDIAC TROPONIN DETERMINATION IN STABLE ISCHEMIC HEART DISEASE: ANALYSIS FROM PROVE IT-TIMI 22 (2013) (1)
Abstract 10398: Vorapaxar in Patients With Diabetes and Prior MI: Findings From the TRA 2P - TIMI 50 Trial (2013) (1)
Is recurrent myocardial infarction following thrombolytic administration associated with long-term mortality? (2002) (1)
Abstract 17338: Development of a TIMI Risk Score for Stable Ischemic Heart Disease (2015) (1)
How are fear-avoidance beliefs associated with objectively-measured physical activity level in osteoarthritis patients? (2018) (1)
Counterfactual inference for sequential experimental design (2022) (1)
Overcoming missing data in a sequential , multiple assignment , randomized clinical trial of patients with schizophrenia (1)
Batch mode reinforcement learning based on the synthesis of artificial trajectories (2012) (1)
Clinical Characteristics, Vascular Function, and Inﬂammation in Women With Angina in the Absence of Coronary Atherosclerosis (2010) (1)
SMARTer discontinuation trials: With application to the treatment of anxious youth (2011) (1)
A mathematical model of preventing plaque rupture with drug-eluting stents based upon distance from the ostium to the culprit lesion in ST elevation myocardial infarction (2003) (1)
Abstract 17307: Biomarkers, Cardiovascular Outcomes and Effect of Ezetimibe After Acute Coronary Syndrome in the IMPROVE-IT Trial (2017) (1)
1101-P: Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58 (2020) (1)
The Relationship of Intracoronary Stent Placement Following Thrombolytic Therapy to Tissue Level Perfusion (2002) (1)
Abstract 979: Novel Nanoparticle Cardiac Troponin I Assay Detects Myocardial Injury in Most Patients with Unstable Angina: Observations from the PROTECT-TIMI 30 Trial (2008) (1)
VORAPAXAR AND PERIPHERAL REVASCULARIZATION: INSIGHTS FOM THE TRA2P-TIMI 50 TRIAL (2015) (1)
Biomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER Trial. (2022) (1)
From Partnership to Program: the Evolution of SHIRP (2017) (1)
Comparison and Unification of Three Regularization Methods in Batch Reinforcement Learning (2021) (1)
Gender differences in cardiac biomarkers in patients with unstable angina and non-ST elevation myocardial infarction in TACTICS-TIMI 18 (2003) (1)
Edoxaban vs. Warfarin in High-risk Patients with Atrial Fibrillation: A Comprehensive Analysis of High-Risk Subgroups. (2022) (1)
Online structural kernel selection for mobile health (2021) (1)
VORAPAXAR AND ACUTE LIMB ISCHEMIA: INSIGHTS FROM THE THROMBIN RECEPTOR ANTAGONIST IN SECONDARY PREVENTION OF ATHEROTHROMBOTIC ISCHEMIC EVENTS-TIMI 50 TRIAL (2015) (1)
A smartphone-based behavioural activation application using recommender system (2019) (1)
EFFICACY AND SAFETY OF VORAPAXAR FOR SECONDARY PREVENTION IN OLDER PATIENTS: OBSERVATIONS FROM TRA 2°P-TIMI 50 (2016) (1)
Comparison of characteristics, treatment, and outcomes of patients enrolled versus not enrolled in a clinical trial: findings from TIMI 9 Registry and 9b trial (2002) (1)
Reply: Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful? (2016) (1)
5719Edoxaban versus warfarin in patients with atrial fibrillation in relation to stroke risk. A subanalysis of the ENGAGE AF-TIMI 48 study (2017) (1)
Abstract 1799: Ranolazine Reduces Ischemia as Detected on Continuous ECG (Holter) in Patients with non-ST-Elevation ACS in the MERLIN - TIMI 36 Trial (2007) (1)
Glycoprotein IIb/IIIa Receptor Inhibition in Interventional Cardiology (1999) (1)
Abstract 314: Impact of Spontaneous Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial (2014) (1)
Abstract 3015: Dynamic Updating of TIMI Risk Score for STEMI: An ExTRACT-TIMI 25 Analysis (2007) (1)
Higher platelet counts are associated with greater thrombus burden in patent arteries following thrombolytic administration: A TIMI angiographic substudy (2003) (1)
Weight-based dosing of thrombolysis: how well do we estimate weight? How often would this translate into errors with administration of thrombolytic drugs? A comparison of single-bolus TNK with t-PA in TIMI 10B (2001) (1)
Abstract 18597: Systemic, Non-cerebral, Arterial Embolism in 21,105 Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Results from the ENGAGE AF-TIMI 48 Trial (2014) (1)
RIVAROXABAN IN THE SETTING OF CONTINUED DUAL ANTIPLATELET THERAPY: FINDINGS FROM THE ATLAS ACS 2-TIMI 51 TRIAL (2013) (1)
Experimental designs for developing adaptive treatment strategies (2011) (1)
Are nights of poor sleep related to greater next-day fatigue and pain in older adults with symptomatic osteoarthritis?: An actigraphy and ecological momentary assessment study (2018) (1)
qlaci R package for using q-learning to construct adaptive interventions using data from a SMART (Version 1.0) (2014) (1)
Biomarkers and Myocardial Ischemia Association of Elevated B-Type Natriuretic Peptide Levels With Angiographic Findings Among Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction (2004) (1)
in a Registry of 3,337 Patients Impact of Aprotinin on Adverse Clinical Outcomes and Mortality up to 12 Years (2013) (1)
Abstract 15581: Effect of Dapagliflozin on Atrial Fibrillation/Flutter in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial (2019) (1)
A risk score for predicting coronary artery bypass surgery in patients with non-ST elevation acute coronary syndromes (2003) (1)
Reward Design For An Online Reinforcement Learning Algorithm Supporting Oral Self-Care (2022) (1)
Dynamic Treatment Regimes using Reinforcement Learning: A Cautious Generalization Approach (2009) (1)
Abstract 2451: Anti-Ischemic Effects of Ranolazine in Women: Results from the Randomized, Placebo-controlled MERLIN-TIMI 36 Trial (2007) (1)
Abstract 15480: The Efficacy and Safety of More Potent Antiplatelet Therapy With Vorapaxar in Patients With Impaired Renal Function: Insights From the TRA 2P-TIMI 50 Trial (2017) (1)
Benefit of invasive strategy for women with acute coronary syndromes: observations from the TACTICS-TIMI 18 trial (2002) (1)
Missing response times in survival analysis (1997) (1)
A Systematic Approach to Job Transitions—Finding Your Way and Landing in Your Best Place (2020) (1)
Aging of intracoronary thrombus due to delayed time-to-reperfusionsincreases ischemic and angiographic complications in acute myocardial infarction (2002) (1)
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. (2023) (1)
Getting SMART about developing individualized sequences of health intervention (2011) (1)
Abstract 20483: Outcomes in Stable Patients With Prior Atherothrombosis Receiving Vorapaxar Who Present With a New Acute Coronary Syndrome: Insights From the TRA2P-TIMI 50 Trial (2014) (1)
Detection of cardiac neurohormonal activation complements cardiac troponin for predicting recurrent events in UA/NSTEMI: prognostic utility of BNP in TACTICS-TIMI 18 (2002) (1)
Determining the risk set for hazard functions when survival methods are applied to social science and prevention data (1997) (1)
Abstract 16198: Evaluation of Multiple Biomarkers of Cardiomyocyte Stress or Injury to Predict Cardiovascular Death or CHF in STEMI: Findings from CLARITY-TIMI 28 (2011) (0)
Greater benefit of early invasive strategy for unstable angina and non-ST elevation myocardial infarction in United States compared with non-United States patients: a TACTICS-TIMI 18 substudy. (2004) (0)
Session: Non/Semi-parametric inferences (2001) (0)
Electrocardiographic left ventricular hypertrophy is associated with mortality and left ventricular rupture in patients with acute myocardial infarction (2002) (0)
Comparison of the frequency and outcomes of investigator assessed recurrent mi versus Clinical Event Committee (CEC) adjudicated recurrent mi in acute MI trials: a TIMI 14 and TIMI 9 substudy (2002) (0)
HEPATIC FAT CHANGES AFTER AN ANTISENSE OLIGONUCLEOTIDE THERAPY TARGETING ANGPTL3: A TRANSLATE-TIMI 70 ANALYSIS (2023) (0)
1021-101 Association of glomerular filtration rate on presentation with subsequent mortality in non-ST elevation acute coronary syndromes (2004) (0)
Abstract 207: Vorapaxar in Patients with Prior Ischemic Stroke: Primary Results from the Stroke Cohort of the Multinational TRA 2°P-TIMI 50 Trial (2013) (0)
Streamlined Empirical Bayes Fitting of Linear Mixed Models in Mobile Health (2020) (0)
Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience) ☆ (2002) (0)
Cost and Effort Considerations for the Development of Intervention Studies Using Mobile Health Platforms: Pragmatic Case Study (2021) (0)
Evaluation of Treatment Policies Assisted by Treatment Eects (2011) (0)
A Review of Some Inferential Challenges in Constructing Dynamic Treatment Regimes (2007) (0)
Abstract PD4-06: Acupressure for persistent fatigue in breast cancer survivors (2016) (0)
Three Lectures on Design of Experiments and Data Analysis in Sequential Decision Making (2015) (0)
APPLICATION OF THE TIMI RISK SCORE, A SIMPLE BEDSIDE TOOL, FOR TIMING OF DISCHARGE AFTER FIBRINOLYSIS OR PRIMARY ANGIOPLASTY FOR ST-ELEVATION MI IN THE EXTRACT-TIMI 25 AND TRITON-TIMI 38 TRIALS (2010) (0)
EVALUATION OF THE DIAGNOSTIC PERFORMANCE OF AN INVESTIGATIONAL ULTRA-SENSITIVE ASSAY FOR CARDIAC TROPONIN I (2011) (0)
Sample size considerations for micro-randomized trials with binary proximal outcomes. (2023) (0)
Reflections on evidence-based rehabilitation practice and applications for chronic pain management. (2013) (0)
Rejoinder: Linear Mixed Models with Endogenous Covariates: Modeling Sequential Treatment Effects with Application to a Mobile Health Study (2020) (0)
Getting SMART about the design of experimental trials for the development of adaptive health interventions (2012) (0)
Abstract 4588: Regional Safety and Efficacy of Prasugrel Compared to Clopidogrel: A TRITON - TIMI 38 Analysis (2008) (0)
A comparison of randomized trials and the multi-phase optimization strategy for behavioral interventions (2005) (0)
Experimental designs for developing adaptive treatment strategies: With application to the management of child anxiety (2008) (0)
Adolescents’ mental health symptoms and technology impairment in daily life (2015) (0)
Abstract 3078: The Impact of Diabetes on Mortality in Acute Coronary Syndromes: An Analysis of 62,035 Patients from the TIMI Study Group (2006) (0)
Re‐adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study‐level meta‐analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase‐4 (DPP‐4) inhibitors (2022) (0)
1098-78 Low hemoglobin predicts worse clinical outcomes in acute coronary syndromes (2004) (0)
An Investigation of Professors' Views on Membership in Professional Organizations (2014) (0)
Adaptive interventions: Healing with data (2016) (0)
1042-86 Risk stratification in ST-segment elevation myocardial infarction with multiple biomarkers (2004) (0)
Introduction to Part III: Markers to mHealth Predictors (2017) (0)
884-5 Impact of Troponin Status and Coronary Artery Disease by Angiography on Outcome in Acute Coronary Syndrome: A TACTICS TIMI-18 Substudy (2004) (0)
General cardiology abstractEarly and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the thrombolysis in myocardial infarction trials☆ (2003) (0)
Elevated white blood cell count is associated with higher mortality in patients with acute coronary syndromes independent of other cardiac markers: a TACTICS - TIMI 18 Substudy (2002) (0)
A batch, off-policy actor-critic algorithm for optimizing mobile interventions (2015) (0)
Online Supplemental Materials to Dynamic Treatment Regimes (2014) (0)
Atrial fibrillation and prior MI: searching for balance in ischaemic and bleeding events in patients treated with factor-specific anticoagulants. (2014) (0)
Program evaluation when there is staff non-compliance (1999) (0)
Response to Letter Regarding Article, "Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel: Thrombolysis in Myocardial Infarc (2009) (0)
SMART designs to improve health (2013) (0)
Abstract 16014: Evaluation of Cardiac Events in ATLAS ACS 2-TIMI 51 (2012) (0)
Major bleeding incidence after coronary artery bypass grafting in patients with unstable angina/non-ST elevation myocardial infarction based on coronary artery bypass graft timing in TACTICS-TIMI-18 (2003) (0)
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58 (2022) (0)
CYSTATIN C IS ASSOCIATED WITH THE RISK OF ADVERSE OUTCOMES INDEPENDENT OF ESTABLISHED AND NOVEL CARDIORENAL MARKERS: AN ANALYSIS FROM THE SOLID-TIMI 52 TRIAL (2017) (0)
Design considerations of mHealth Platforms for Real-Time Intervention Studies: Evaluative Framework and Proof-of-Concept Study (Preprint) (2021) (0)
Is there a role for half-dose anticoagulation in atrial fibrillation? Randomized comparison of 2 doses of edoxaban in 14,014 patients in ENGAGE AF-TIMI 48 (2020) (0)
P285Comparison of analysis methodologies for net outcome with edoxaban vs warfarin in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial (2018) (0)
Variable selection for tailoring treatment (2008) (0)
C-TERMINAL PROVASOPRESSIN (COPEPTIN), MID-REGION PRO-ADRENOMEDULLIN (MR-PROADM) AND MID-REGION PRO-ATRIAL NATRIURETIC PEPTIDE (MR-PROANP) AS NOVEL PROGNOSTIC BIOMARKERS AFTER NON-ST ELEVATION ACUTE CORONARY SYNDROME: ANALYSIS FROM MERLIN TIMI-36 (2011) (0)
EDOXABAN 30 MG VS WARFARIN IN 2,406 PATIENTS AGE ≥80 YEARS: A RANDOMIZED ANALYSIS FROM ENGAGE AF-TIMI 48 (2023) (0)
myocardial infarction with subsequent mortality Association of creatinine and creatinine clearance on presentation in acute (2011) (0)
Current Shocks and Prevents Left Ventricuiar Dysfunction in an In Vivo Swine Model (2002) (0)
302A ABSTRACTS- Myocardial Ischemia and Infarction (2016) (0)
Triple Therapy: Aspirin, Thienopyridine and Oral Anticoagulation Therapy Following STEMI: Is it Safe? (2009) (0)
Myocardial infarction accelerates (2012) (0)
Abstract 20145: ST2 and the Risk of CV Death or Heart Failure in Patients with Non-ST elevation Acute Coronary Syndromes (NSTE-ACS): Observations from MERLIN-TIMI 36 (2010) (0)
FROM THE DESK OF THE EDITOR AND ASSOCIATE EDITOR Intervention Fidelity: A Necessary Aspect of Intervention (2015) (0)
Lipoprotein-Associated Phospholipase A 2 and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction) Trial Coronary Heart Disease (2006) (0)
INTERINDIVIDUAL VARIABILITY IN WEIGHT LOSS WITH LORCASERIN: AN ANALYSIS FROM THE CAMELLIA-TIMI 61 STUDY (2019) (0)
Evaluation of the atrial fibrillation better care pathway in the ENGAGE AF-TIMI 48 trial. (2022) (0)
Abstract 1473: Central Obesity and Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Observations From the MERLIN-TIMI 36 Trial (2009) (0)
Small Sample Prediction Intervals for the Test Error In Classification (2008) (0)
INTERINDIVIDUAL VARIABILITY IN WEIGHT LOSS WITH LORCASERIN: AN ANALYSIS FROM THE CAMELLIA-TIMI 61 STUDY (2019) (0)
Experimental designs for developing adaptive treatment strategies: With application to the management of bipolar disorder (2010) (0)
Abstract 12577: The Efficacy and Safety of Third Generation P2Y12 Inhibitors in Women versus Men: A Sex-Specific Meta-Analysis (2015) (0)
ssociation of Duration of Symptoms at resentation With Angiographic and Clinical utcomes After Fibrinolytic Therapy in Patients ith ST-Segment Elevation Myocardial Infarction (2016) (0)
Abstract 14770: Reduction With Evolocumab in Complex Coronary Disease Requiring Revascularization: Insights From the FOURIER Trial (2020) (0)
Introduction to Part II: Sensors to mHealth Markers (2017) (0)
The association between pain threshold and adaptive and maladaptive coping strategies in adults with symptomatic knee and hip osteoarthritis (2012) (0)
The Prevention and Treatment of Missing Data in Clinical Trials. Pannel on Handling Missing Data in Clinical Trials (2010) (0)
Stitched Trajectories for Off-Policy Learning (2018) (0)
TCT-196 PCI Versus CABG for Left Main Disease in Patients Presenting With Versus Without an Acute Coronary Syndrome (2022) (0)
P4808Edoxaban and implantable cardiac device interventions - Insights from the ENGAGE AF-TIMI 48 trial (2018) (0)
Introduction to Part IV: Predictors to mHealth Interventions (2017) (0)
Abstract 3163: Association of Pre-PCI TIMI flow grade (TFG) with Subsequent Mortality in Patients Presenting with ST-Elevation Myocardial Infarction (STEMI) (2007) (0)
1021-102 Underachievement of low-density lipoprotein cholesterol goal in patients on statins in clinical practice: Are we using low doses of stains too often? (2004) (0)
Abstract 19878: Metalloproteinase PAPP-A and Outcomes in Patients with ACS: Observations from the MERLIN-TIMI 36 Trial (2010) (0)
Optimizing an Acceptance and Commitment Therapy Microintervention Via a Mobile App With Two Cohorts: Protocol for Micro-Randomized Trials (Preprint) (2019) (0)
An Investigation of Professors’ Views on Membership in Professional Organizations Web Appendix (2014) (0)
REDUCTION IN TOTAL CARDIOVASCULAR EVENTS WITH THE PCSK9 INHIBITOR EVOLOCUMAB IN PATIENTS WITH CARDIOVASCULAR DISEASE IN THE COMBINED FOURIER AND FOURIER OPEN-LABEL EXTENSION (OLE) STUDIES (2023) (0)
Learning Treatment Policies in Mobile Health (2016) (0)
98 Feasibility and acceptability of using a mobile phone app to assess substance use among adolescents and emerging adults (2017) (0)
P ost-Effectiveness of Distal Embolic Protection or Patients Undergoing Percutaneous ntervention of Saphenous Vein Bypass Grafts (2016) (0)
Acute Myocardial Infarction ssociation of a Pulsatile Blood Flow Pattern n Coronary Arteriography and Short-Term linical Outcomes in Acute Myocardial Infarction (2016) (0)
Breaking Conceptual Barriers to Information Architecture: An Online Learning Experience (2011) (0)
Erratum to: Evaluation of the diagnostic performance of heart-type fatty acid binding protein in the BWH-TIMI ED chest pain study (2013) (0)
- Type Natriuretic Peptide at resentation and Prognosis in Patients ith ST-Segment Elevation Myocardial Infarction n ENTIRE – TIMI-23 Substudy essica (2016) (0)
UNIVERSAL CLASSIFICATION SYSTEM TYPE OF INCIDENT MYOCARDIAL INFARCTION IN PATIENTS WITH STABLE ATHEROSCLEROSIS: OBSERVATIONS FROM TRA 2°P-TIMI 50 (2014) (0)
Abstract TP121: Predictors of Ischemic Stroke in Patients with Atherosclerotic Vascular Disease: Observations from the TRA 2°P-TIMI 50 Trial (2013) (0)
ACUPRESSURE FOR PERSISTENT CANCER RELATED FATIGUE 1 2 (2016) (0)
Is the inhibition of the PAR-1 receptor with vorapaxar associated with anti-inflammatory effects in patients with symptomatic atherosclerosis: observations from TRA 2P-TIMI 50 (2013) (0)
Learning Treatment Policies in Mobile Health in Mobile Health (2015) (0)
EDOXABAN VERSUS WARFARIN IN ATRIAL FIBRILLATION ABLATION: FIRST EXPERIENCE FROM THE ENGAGE AF TIMI 48 TRIAL (2017) (0)
Infarction Following Fibrinolytic Therapy for ST-Segment Elevation Myocardial Perfusion Grade With Ventricular Tachycardia and Ventricular Fibrillation Association of Impaired Thrombolysis In Myocardial Infarction Myocardial (2011) (0)
Supplementary Material for “Sample Size Formulae for Two-Stage Randomized Trials with Censored Data” (2011) (0)
Inferring bounds on the performance of a control policy from a sample of one-step system transitions (2009) (0)
SMART approaches to combating autism (2013) (0)
Rejoinder (2011) (0)
Abstract 3299: Efficacy and Safety of Enoxaparin vs. UFH in Patients with ST-Elevation Myocardial Infarction Also Treated Or Not Treated with Clopidogrel: Analysis from ExTRACT-TIMI 25 (2006) (0)
The Penn State Methodology Center: Bringing the power of innovative methods to bear on drug abuse (2009) (0)
Piloting and sizing sequential, multiple assignment, randomized trials in dynamic treatment regime development (2012) (0)
Using data to inform sequential, individualized clinical decision making (2011) (0)
Serial measurement of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48 (2020) (0)
Abstract 2385: Cystatin C is Associated with Left Ventricular Mass Independent of Traditional Markers of Renal Function in a Multiethnic Population-based Sample: The Dallas Heart Study (2007) (0)
Principal Stratification, Partial Contingency Table, and Statistical Leverage (2007) (0)
Delivering Precision Behavior Change Through Digital Medicine (2018) (0)
PROCEDURAL BLEEDING WITH VORAPAXAR VERSUS PLACEBO IN THE TRA 2°P-TIMI 50 TRIAL (2013) (0)
Abstract 2486: Impaired Myocardial Perfusion at the End of Percutaneous Coronary Intervention (PCI) is Associated with Continuous ECG Ischemia Immediately Following PCI which is then Associated with Myonecrosis Hours Later. A PROTECT-TIMI 30 Substudy (2006) (0)
84 A follow-up evaluation of an expanded good clinical practice online training course: The relevance of community engagement to health research study teams. (2023) (0)
Predictors of Intracranial Hemorrhage in Patients with Atherosclerotic Vascular Disease: Observations from the TRA 2 degrees P-TIMI 50 Trial (2013) (0)
1118-82 Distinct modes of cardiovascular death associated with impaired epicardial and myocardial perfusion following fibrinolysis for ST elevation myocardial infarction (2004) (0)
Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes Clinical Investigation and Reports (2003) (0)
GALECTIN-3 AND THE DEVELOPMENT OF HEART FAILURE AFTER ACUTE CORONARY SYNDROME: A PILOT EXPERIENCE FROM PROVE IT-TIMI 22 (2011) (0)
116 The long-term impact of a practice-oriented research training program for clinical and translational research staff and clinicians: Evaluating workforce development outcomes over time and professional careers. (2023) (0)
Adherence to Upper-Extremity Home Exercise Delivered via Mobile App for People With Systemic Sclerosis (2020) (0)
Methodology for adaptive treatment strategies for chronic disorders: Focus on pain (2010) (0)
Privacy-aware multi-institutional time-to-event studies (2022) (0)
PROGNOSTIC VALUE OF SERIAL C-REACTIVE PROTEIN LEVELS AFTER AN ACUTE CORONARY SYNDROME: AN ANALYSIS FROM PROVE-IT TIMI 22 (2012) (0)
Abstract 10083: The Efficacy and Safety of Dapagliflozin in Women and Men With Type 2 Diabetes Mellitus: Insights From The DECLARE-TIMI 58 Trial (2019) (0)
Increased platelet receptor occupancy following eptifibatide therapy is associated with improved patency, tissue level perfusion, and ST-segment resolution in ST-segment elevation myocardial infarction: An INTEGRITI substudy (2003) (0)
Associations of Coexisting Pain and Fatigue Severity with Physical Performance and Quality of Life among Middle-Aged and Older Individuals with Chronic Knee Pain: A randomized controlled trial. (2021) (0)
1060-101 Angiographically apparent thrombus after fibrinolytic administration is associated with impaired epicardial flow and myocardial perfusion in ST elevation myocardial infarction patients with open arteries (2004) (0)
P Acute Myocardial Infarction rognostic Implications of Elevated Troponin n Patients With Suspected Acute Coronary yndrome But No Critical Epicardial Coronary Disease TACTICS-TIMI-18 Substudy (2016) (0)
Chapter 11: Imputing missing data from sequential multiple assignment randomized trials (2015) (0)
Abstract 3006: The Association of Culprit and Non-Culprit Myocardial Perfusion with Clinical Events Following an ST-Elevation MI (STEMI): An Analysis from the CLARITY-TIMI 28 Study (2007) (0)
Diminution in flow following primary stenting in the INAMI study (2003) (0)
Abstract TP297: Predictors of Intracranial Hemorrhage in Patients with Atherosclerotic Vascular Disease: Observations from the TRA 2°P-TIMI 50 Trial (2013) (0)
410Heart failure risk stratification and efficacy of dapagliflozin in patients with type 2 diabetes mellitus (2019) (0)
T-wave alternans in patients with heart failure (ALPHA) (2007) (0)
Glyceryl trinitrate for acute stroke: Main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial (2014) (0)
Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". (2016) (0)
A robust MPC approach to the design of treatments. (2013) (0)
Experimental design, data analysis,methods for mobile interventions (2015) (0)
1060-83 Calcification of the culprit lesion is associated with adverse clinical outcomes in ST elevation myocardial infarction patients treated with fibrinolytic therapy (2004) (0)
Abstract 14419: Natural History of Atherothrombotic Events According to the Primary Diseased Vascular Bed - Insights from the TRA2P-TIMI 50 Trial (2012) (0)
788-P: The Cardiovascular and Renal Benefits of Dapagliflozin Are Independent of Baseline HbA1c: Analyses from DECLARE-TIMI 58 (2021) (0)
Modeling Mobile Health Users as Reinforcement Learning Agents (2022) (0)
Heart failure following ST elevation myocardial infarction: Are we aggressive enough? (2003) (0)
884-4 Higher levels of thrombus precursor protein are associated with increased death and ischemic complications in patients with acute coronary syndromes (2004) (0)
Poster 134 Heterogeneity of Symptoms among Adults with Osteoarthritis: Implications for Rehabilitation (2011) (0)
Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". (2018) (0)
THE ROLE OF VORAPAXAR IN PATIENTS WITH CORONARY ARTERY BYPASS GRAFTING: FINDINGS FROM THE TRA 2P-TIMI 50 TRIAL (2015) (0)
Abstract 3211: Baseline Clinical Risk and Recurrent Ischemia as Detected on Continuous ECG (CECG) Monitoring in Patients with non-ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial (2007) (0)
Machine learning methods for individualizing real-time treatment policies (2013) (0)
Personalizing Intervention Probabilities By Pooling (2018) (0)
Data-driven Interpretable Policy Construction for Personalized Mobile Health (2022) (0)
Developing adaptive health interventions: Getting SMART (2012) (0)
Time-varying causal effect moderation in the presence of time-varying confounding using structural nested mean models (2010) (0)
Developing dynamic, sequential interventions that optimize mental health outcomes: Novel clinical trial design and data analysis strategies (2011) (0)
Relationship Between the Theory of Planned Behavior, Mobility Impairment and Physical Activity in Older Adults: 1951 (2007) (0)
Full Factorial Screening Experiments for Adaptive Treatment Strategies (2006) (0)
Getting SMART about Adapting Interventions (2013) (0)
Abstract WP310: Outcomes after Intracranial Hemorrhage in Patients with Atherosclerotic Vascular Disease: Observations from the TRA 2°P-TIMI 50 Trial (2013) (0)
LIKELIHOOD INFERENCEIN THE ERRORS-IN-VARIABLES MODELBY (1996) (0)
1097-97 Safety of stress testing following an acute coronary syndrome (2004) (0)
Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y 12 Antagonist, With Clopidogrel in Percutaneous Coronary Intervention Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)–TIMI 26 Trial Coronary Heart Disease (2005) (0)
(374) Acceptability and Effects of Using Wearable Activity Trackers for Chronic Pain Management among Older African American Adults (2019) (0)
Highlights From the Circulation Family of Journals (2017) (0)
Treatment and outcomes of eastern European patients with acute coronary syndromes in a multinational randomized clinical trial (2003) (0)
The purpose of the Institute is to foster the development and dissemination of the theory and applications of statistics and probability. (2016) (0)
Angiographic Parameters Impact of Saphenous Vein Graft Radiographic Markers on Clinical Events and (2013) (0)
ASSOCIATION OF BASELINE LIPOPROTEIN(A) AND PERCENTAGE OF LIPOPROTEIN(A) LOWERING WITH OLPASIRAN (2023) (0)
Abstract 18549: High-sensitivity Troponin I in Stable Patients With Atherosclerotic Disease in the TRA2°P- TIMI 50 Trial (2015) (0)
Rejoinder (2000) (0)
On SMART and factorial designs: Application to mHealth research (2014) (0)
Power Constrained Bandit (2021) (0)
Randomized Controlled Trial Thrombolysis in Myocardial − ST-Elevation Acute Coronary Syndrome − Ischemia in Non Coronary Syndrome : Results From the Metabolic Efficiency (2007) (0)
BIOMARKER PREDICTION OF MAJOR CORONARY EVENTS AND COMPLEX REVASCULARIZATION PROCEDURES IN PATIENTS WITH STABLE ATHEROSCLEROSIS (2021) (0)
The impact of clinical judgment in a conduct problems prevention project for high-risk children and their families (2001) (0)
– Addressing the Computational Challenges of Personalized Medicine 2 Table of Contents (2018) (0)
Abstract 5017: Osteoprotegerin and the Risk of Recurrent Events in Patients With Non-ST elevation Acute Coronary Syndromes (NSTE-ACS): Observations From MERLIN-TIMI 36 (2009) (0)
An angiographic risk score integrating both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute MI (2002) (0)
A simple electrocardiographic method to predict patency of the infarct-related artery after fibrinolytic therapy (2003) (0)
Sample Size Calculation for Comparing Two-Stage Treatment Strategies with Censored Data (2009) (0)
A simple ECG method using high-risk infarct territory is superior to ECGs using summed ST elevation for assessing risk in ST elevation myocardial infarction (2003) (0)
Abstract 3995: Comparison of the Effects of Prasugrel and High Dose Clopidogrel on In Vivo and In Vitro Platelet Activation: Results from PRINCIPLE-TIMI 44 (2008) (0)
SMART study designs for developing interventions (2014) (0)
Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58. (2022) (0)
Neutrophil-Lymphocyte Ratio and Clinical Outcomes in 19,697 Patients with Atrial Fibrillation: Analyses from ENGAGE AF-TIMI 48 Trial (2023) (0)
Abstract 5338: Universal Definition of Myocardial Infarction Classification and the Risk of Cardiovascular Death: Observations From the TRITON-TIMI 38 Trial (2009) (0)
Percutaneous coronary intervention during the index hospitalization is associated with reduced recurrent myocardial infarction and improved survival following thrombolytic administration (2003) (0)
LONG-TERM THIENOPYRIDINE THERAPY AND OUTCOMES IN PATIENTS WITH ACS TREATED WITH CORONARY STENTING: THE PRIMARY RESULTS OF THE TIMI-38 CORONARY STENT REGISTRY (2011) (0)
303-OR: Effect of Dapagliflozin on Risk for Fast Decline in EGFR: Analyses from the DECLARE-TIMI 58 Trial (2020) (0)
Abstract 16688: Effects of Evolocumab in Patients With Prior Percutaneous Coronary Intervention: An Analysis From the Fourier Trial (2020) (0)
Abstract 4048: Independent and Additive Influence of Metabolic Syndrome and Diabetes Mellitus on Atherosclerosis: Observations from the Dallas Heart Study (2006) (0)
Introduction to Part I: mHealth Applications and Tools (2017) (0)
BLEEDING IN STABLE PATIENTS WITH ATHEROSCLEROTIC DISEASE: INSIGHTS FROM TRA2°P- TIMI 50 TRIAL (2016) (0)
Exploratory Analysis of Practical Trial Data for Informing the Individualization Of Treatment (2009) (0)
CONSISTENCY OF LDL-C REDUCTION WITH EVOLOCUMAB: AN ANALYSIS FROM FOURIER (2018) (0)
Abstract 17350: Multimarker Risk Stratification in Patients with Acute Myocardial Infarction (2014) (0)
Abstract 3938: Gender Differences in the Relationship Between Family History of Myocardial Infarction and Cardiovascular Disease Risk Factors and Awareness in Young Subjects: the Dallas Heart Study (2006) (0)
ATHEROTHROMBOTIC RISK STRATIFICATION AND EZETIMIBE USE IN IMPROVE-IT (2016) (0)
25.4 AN ADAPTIVE TREATMENT STRATEGY FOR ADOLESCENT DEPRESSION: BEGINNING WITH NBSP; INTERPERSONAL PSYCHOTHERAPY FOR DEPRESSED ADOLESCENTS (2016) (0)
Abstract 1707: Admission Glucose and Cardiovascular Outcomes in Patients With Non-ST Elevation ACS: Observations From the MERLIN-TIMI 36 Trial (2009) (0)
Clinical Tria Randomized Trial to Evaluate the elative Protection Against Post-Percutaneous oronary Intervention Microvascular ysfunction , Ischemia , and Inflammation mong Antiplatelet and Antithrombotic Agents he PROTECT – TIMI-30 Trial (2006) (0)
CARDIOPROTECTION AND PLAQUE REGRESSION WITH MEDI6012 IN ACUTE ST ELEVATION MYOCARDIAL INFARCTION - PRIMARY RESULTS OF THE REAL-TIMI 63B RANDOMIZED CLINICAL TRIAL (2021) (0)
Abstract 1676: Evaluation of Continuous Holter Monitoring Following Percutaneous Coronary Intervention (PCI) as a Surrogate for Post-PCI Myonecrosis: An Analysis from The PROTECT-TIMI 30 Trial (2007) (0)
NEUTROPHIL-LYMPHOCYTE RATIO AND OUTCOMES IN PATIENTS WITH ATRIAL FIBRILLATION: ANALYSES FROM ENGAGE AF-TIMI 48 TRIAL (2022) (0)
Abstract 1733: Race and Gender Differences in Lipoprotein-Associated Phospholipase A2 Levels: Results From the Dallas Heart Study (2006) (0)

This paper list is powered by the following services:

Other Resources About Susan Murphy

What Schools Are Affiliated With Susan Murphy?

Susan Murphy is affiliated with the following schools:

Susan Murphy's Academic­Influence.com Rankings